Single-Tablet HIV Regimen Submitted for FDA Review

A new drug application has been submitted to the FDA for an investigational single-tablet regimen that combines dolutegravir, abacavir, and lamivudine for the treatment of patients with human immunodeficiency virus-1 infection.

http://www.pharmscope.com/news/DailyDetail.cfm?chosen=67930